Home › Rhabdoid Tumor
Pag-aaral pangklinika para sa Rhabdoid Tumor na nagre-recruit sa U.S.
17 pag-aaral para sa Rhabdoid Tumor ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Washington, DC5 pag-aaral
- Houston, TX4 pag-aaral
- Birmingham, AL3 pag-aaral
- St. Louis, MO3 pag-aaral
- Mountain View, CA3 pag-aaral
Ayos sa estado
- Alabama3 pag-aaral
- California4 pag-aaral
- District of Columbia5 pag-aaral
- Missouri3 pag-aaral
- Tennessee3 pag-aaral
- Texas6 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07087002NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
Nagre-recruitPhase 1
Edad 3 hanggang 25 · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07664176HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Nagre-recruitPhase 1
36 Months – 22 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03911388Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Nagre-recruitPhase 1/2
Hanggang edad 26 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06465199B7-H3.CD28Z.CART in CNS Neoplasms
Nagre-recruitPhase 1
Edad 2 hanggang 21 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07390539Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT04715191C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Nagre-recruitPhase 1
12 Months – 25 Years · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT04099797Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06625190Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
Nagre-recruitPhase 2
Edad 1 hanggang 39 · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT07447076Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT06193759B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update May 19, 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Nagre-recruitPhase 2
12 Months · Lahat ng kasarian · Na-update May 6, 2026 · NCT05985161Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Nagre-recruitPhase 1
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT04185038Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Nagre-recruitPhase 1
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update Nob 3, 2025 · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nagre-recruitPhase 2
18 Months – 40 Years · Lahat ng kasarian · Na-update Ago 12, 2025 · NCT05135975Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.